INS and diabetes mellitus: With numerous recombinant insulin innovators and biosimilar products currently marketed in the USA, ongoing manufacturing and product quality research continue to refine insulin therapies, addressing the clinical and economic burden of diabetes while improving the quality of insulin products and, by extension, the quality of life for millions of patients.